Wilson ventures into gene editing with iECURE launch, backed by $50M series A

Gene therapy pioneer James Wilson is expanding his entrepreneurial vision into gene editing with the launch of iECURE, a company tackling the challenging gene editing application of in vivo gene insertion. 

iECURE launched on Thursday with a $50 million series A round led by OrbiMed Advisors and Versant Ventures, plus collaborations with the University of Pennsylvania and Precision BioSciences Inc. (NASDAQ:DTIL) that give the start-up options to 13 in vivo, liver-targeting gene editing programs. ...